Evidence map›Paper›PMID 39195212›Full record

ArticleCells2024

Analysis of the Effector Functions of Vδ2 γδ T Cells and NK Cells against Cholangiocarcinoma Cells.

Inthuon Kulma, Kesara Na-Bangchang, Andrea Carvallo Herrera, Ifeanyi Theodora Ndubuisi, Masashi Iwasaki, Hiromi Tomono, Craig T Morita, Haruki Okamura, Hiroshi Mukae, Yoshimasa Tanaka

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Inthuon KulmaCenter for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.ORCID 0000-0001-7213-9085
Kesara Na-BangchangGraduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani 12121, Thailand.
Andrea Carvallo HerreraCenter for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.
Ifeanyi Theodora NdubuisiCenter for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.
Masashi IwasakiCenter for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Hiromi TomonoDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.ORCID 0009-0006-2748-9418
Craig T MoritaDepartment of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA.ORCID 0000-0001-8496-8294
Haruki OkamuraLaboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.
Yoshimasa TanakaCenter for Medical Innovation, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan.ORCID 0000-0002-5024-0614

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Metabolic Engineering of Bacteria for Cancer Immunotherapy by Gamma Delta T CellsI01BX000972 · VA · IOWA CITY VA MEDICAL CENTER · PI MORITA, CRAIG T · 2012 to 2023
–
AMED 23ama121032j0002AMED A48AMED A90BLRD VA I01 BX000972Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development 2I01 BX000972-05JST JPMJST2281MEXT 16K08844MEXT 23K06677MEXT JP223fa627004NCI NIH HHS P30 CA086862Thailand Research Fund under the Royal Golden Jubilee Ph.D. Program PHD/0096/2560Thailand Science Research and Innovation Fundamental Fund and the National Research Council of Thailand under the Research Team Promotion grant NRCT 820/2563
6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is a rare disease characterized by malignant cells derived from the epithelial cells of the biliary duct system. Despite extensive treatments, the prognosis for CCA remains poor, emphasizing the critical need for the development of novel treatments. Considerable attention has been directed towards innate immune effector cells, which can recognize tumor cells independently of the major histocompatibility complex, laying the foundation for the development of off-the-shelf drugs. In this study, we cultured innate immune cells obtained from the peripheral blood of healthy adults and conducted a comparative analysis of the effector functions against CCA cell lines by Vδ2 γδ T cells and NK cells. This analysis was performed using standard short- and long-term cytotoxicity assays, as well as ELISA for IFN-γ. Vδ2 γδ T cells demonstrated cytotoxicity and IFN-γ production in response to CCA cells in a TCR-dependent manner, particularly in the presence of tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate, a bisphosphonate prodrug. In contrast, direct killing and antibody-dependent cellular cytotoxicity were relatively slow and weak. Conversely, NK cells displayed potent, direct cytotoxicity against CCA cells. In summary, both Vδ2 γδ T cells and NK cells show promise as innate immune effector cells for adoptive transfer therapy in the context of CCA.

Indexed as

CholangiocarcinomaInterferon-gammaKiller Cells, NaturalReceptors, Antigen, T-Cell, gamma-deltaBile Duct NeoplasmsCell Line, TumorCytotoxicity, ImmunologicHumansIntraepithelial LymphocytesT-LymphocytesInterferon-gammaReceptors, Antigen, T-Cell, gamma-deltabisphosphonatecancer immunotherapycholangiocarcinomainterleukin-18natural killer cellγδ T cell

Identifiers

PMID39195212
PMCPMC11352430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.